Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of First Line Pembrolizumab in Combination With Trastuzumab, Capecitabine, and Cisplatin in HER2 Positive Gastric Cancer

NCT02901301 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT02901301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02901301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of First Line Pembrolizumab in Combination With Trastuzumab, Capecitabine, and Cisplatin in HER2 Positive Gastric Cancer
Lead sponsor
Yonsei University
Phase
Phase 1/2
Overall status
Unknown status
Start date
February 6, 2017
Completion date
October 31, 2021
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer